These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 27116457

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability.
    Mbatchi LC, Brouillet JP, Evrard A.
    Pharmacogenomics; 2018 Jan; 19(1):61-77. PubMed ID: 29199543
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
    Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M.
    Clin Cancer Res; 2008 Mar 15; 14(6):1788-96. PubMed ID: 18347181
    [Abstract] [Full Text] [Related]

  • 5. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
    Ferraldeschi R, Minchell LJ, Roberts SA, Tobi S, Hadfield KD, Blackhall FH, Mullamitha S, Wilson G, Valle J, Saunders M, Newman WG.
    Pharmacogenomics; 2009 May 15; 10(5):733-9. PubMed ID: 19450125
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.
    Gibbs P, Brown TJ, Ng R, Jennens R, Cinc E, Pho M, Michael M, Fox RM.
    Chemotherapy; 2009 May 15; 55(1):49-59. PubMed ID: 19060478
    [Abstract] [Full Text] [Related]

  • 9. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
    Fujita K, Kubota Y, Ishida H, Sasaki Y.
    World J Gastroenterol; 2015 Nov 21; 21(43):12234-48. PubMed ID: 26604633
    [Abstract] [Full Text] [Related]

  • 10. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
    Nagar S, Blanchard RL.
    Drug Metab Rev; 2006 Nov 21; 38(3):393-409. PubMed ID: 16877259
    [Abstract] [Full Text] [Related]

  • 11. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y.
    Cancer Sci; 2011 Oct 21; 102(10):1868-73. PubMed ID: 21740478
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.
    Di Paolo A, Bocci G, Danesi R, Del Tacca M.
    Curr Clin Pharmacol; 2006 Sep 21; 1(3):311-23. PubMed ID: 18666754
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nuclear receptors and drug metabolism for the personalization of cancer therapy.
    Cecchin E, De Mattia E, Toffoli G.
    Expert Opin Drug Metab Toxicol; 2016 Sep 21; 12(3):291-306. PubMed ID: 26789519
    [Abstract] [Full Text] [Related]

  • 15. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
    Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E, Kim RB.
    Br J Cancer; 2015 Mar 03; 112(5):857-65. PubMed ID: 25611302
    [Abstract] [Full Text] [Related]

  • 16. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics.
    Lamba J, Lamba V, Schuetz E.
    Curr Drug Metab; 2005 Aug 03; 6(4):369-83. PubMed ID: 16101575
    [Abstract] [Full Text] [Related]

  • 17. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.
    Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalcberg JR.
    J Clin Oncol; 2006 Sep 10; 24(26):4228-35. PubMed ID: 16896007
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Analysis of common polymorphisms within NR1I2 and NR1I3 genes and tacrolimus dose-adjusted concentration in stable kidney transplant recipients.
    Kurzawski M, Malinowski D, Dziewanowski K, Droździk M.
    Pharmacogenet Genomics; 2017 Oct 10; 27(10):372-377. PubMed ID: 28777242
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.